Urs B Hagemann
Overview
Explore the profile of Urs B Hagemann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
440
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hagemann U, Schatz C, Suominen M, Schlicker A, Knuuttila M, Wilson T, et al.
Int J Mol Sci
. 2025 Jan;
25(24.
PMID: 39769434
Despite treatment, prostate cancer commonly progresses into castration-resistant prostate cancer (CRPC), which remains largely incurable, requiring the development of new interventions. Darolutamide is an orally administered second-generation androgen receptor inhibitor...
2.
Schatz C, Zitzmann-Kolbe S, Moen I, Klotz M, Nair S, Stargard S, et al.
Clin Cancer Res
. 2024 Apr;
30(11):2531-2544.
PMID: 38593212
Purpose: Initially, prostate cancer responds to hormone therapy, but eventually resistance develops. Beta emitter-based prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy is approved for the treatment of metastatic castration-resistant prostate cancer....
3.
Karlsson J, Hagemann U, Cruciani V, Schatz C, Grant D, Ellingsen C, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444529
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-30% of breast cancers but has low expression in normal tissue, making it attractive for targeted alpha therapy (TAT). HER2-positive...
4.
Zitzmann-Kolbe S, Kristian A, Zopf D, Kamfenkel C, Politz O, Ellingsen C, et al.
Mol Cancer Ther
. 2023 Jun;
22(9):1073-1086.
PMID: 37365121
Targeted alpha therapies (TAT) are an innovative class of therapies for cancer treatment. The unique mode-of-action of TATs is the induction of deleterious DNA double-strand breaks. Difficult-to-treat cancers, such as...
5.
Karlsson J, Schatz C, Wengner A, Hammer S, Scholz A, Cuthbertson A, et al.
Front Med (Lausanne)
. 2023 Feb;
9:1071086.
PMID: 36726355
Targeted alpha therapy (TAT) is a promising approach for addressing unmet needs in oncology. Inherent properties make α-emitting radionuclides well suited to cancer therapy, including high linear energy transfer (LET),...
6.
Broer L, Knapen D, Suurs F, Moen I, Giesen D, Waaijer S, et al.
J Nucl Med
. 2022 Apr;
63(11):1715-1721.
PMID: 35422447
The mesothelin (MSLN)-targeted Th conjugate is a novel α-therapy developed to treat MSLN-overexpressing cancers. We radiolabeled the same antibody-chelator conjugate with Zr to evaluate whether PET imaging with Zr-MSLN matches...
7.
Lejeune P, Cruciani V, Berg-Larsen A, Schlicker A, Mobergslien A, Bartnitzky L, et al.
J Immunother Cancer
. 2021 Oct;
9(10).
PMID: 34615703
Background: Targeted thorium-227 conjugates (TTCs) are an emerging class of targeted alpha therapies (TATs). Their unique mode of action (MoA) is the induction of difficult-to-repair clustered DNA double-strand breaks. However,...
8.
Hammer S, Schlicker A, Zitzmann-Kolbe S, Baumgart S, Hagemann U, Scholz A, et al.
Clin Cancer Res
. 2021 May;
27(15):4367-4378.
PMID: 34035067
Purpose: Androgen receptor (AR) inhibitors are well established in the treatment of castration-resistant prostate cancer and have recently shown efficacy also in castration-sensitive prostate cancer. Although most patients respond well...
9.
Roy J, Jagoda E, Basuli F, Vasalatiy O, Phelps T, Wong K, et al.
Cancer Biother Radiopharm
. 2021 May;
36(4):316-325.
PMID: 34014767
[Th]Th-3,2-HOPO-MSLN-mAb, a mesothelin (MSLN)-targeted thorium-227 therapeutic conjugate, is currently in phase I clinical trial; however, direct PET imaging using this conjugate is technically challenging. Thus, using the same MSLN antibody,...
10.
Hagemann U, Wickstroem K, Hammer S, Bjerke R, Zitzmann-Kolbe S, Ryan O, et al.
Cancer Biother Radiopharm
. 2020 Apr;
35(7):497-510.
PMID: 32255671
Targeted α therapy (TAT) offers the potential for the targeted delivery of potent α-particle-emitting radionuclides that emit high linear energy transfer radiation. This leads to a densely ionizing radiation track...